Clinton Snow
Director/Board Member bei ICETANA LIMITED
Profil
Clinton Snow is currently a Non-Executive Director at Dimerix Ltd., PolyActiva Pty Ltd., and iCetana Ltd.
He completed his undergraduate degree at the University of Melbourne.
Aktive Positionen von Clinton Snow
Unternehmen | Position | Beginn |
---|---|---|
ICETANA LIMITED | Director/Board Member | 08.02.2022 |
DIMERIX LIMITED | Director/Board Member | 01.05.2023 |
PolyActiva Pty Ltd.
PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Director/Board Member | - |
Ausbildung von Clinton Snow
University of Melbourne | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
DIMERIX LIMITED | Health Technology |
ICETANA LIMITED | Technology Services |
Private Unternehmen | 1 |
---|---|
PolyActiva Pty Ltd.
PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Health Technology |